Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus added to bendamustine and rituximab for relapsed follicular or mantle cell lymphoma
2009-013351-30Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus, bendamustine and rituximab in follicular lymphoma (FL) and mantle cell lymphoma (MCL), sponsored by University Medical Center Mainz. Primary endpoint: Safety and feasibility. Started Oct 2009; status: completed.
02
Drugs
temsirolimusbendamustinerituximab
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2009-013351-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013351-30.